Literature DB >> 30760464

Resistance mechanism for ibrutinib in marginal zone lymphoma.

Narendranath Epperla1, Arwa Y Shana'ah2, Dan Jones2, Beth A Christian1, Sabarish Ayyappan1, Kami Maddocks1, Jennifer A Woyach1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30760464      PMCID： PMC6391658          DOI： 10.1182/bloodadvances.2018029058

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  12 in total

Review 1.  Targeted therapies in CLL: mechanisms of resistance and strategies for management.

Authors:  Jennifer A Woyach; Amy J Johnson
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

Review 2.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

3.  Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.

Authors:  Ariela Noy; Sven de Vos; Catherine Thieblemont; Peter Martin; Christopher R Flowers; Franck Morschhauser; Graham P Collins; Shuo Ma; Morton Coleman; Shachar Peles; Stephen Smith; Jacqueline C Barrientos; Alina Smith; Brian Munneke; Isaiah Dimery; Darrin M Beaupre; Robert Chen
Journal:  Blood       Date:  2017-02-06       Impact factor: 22.113

4.  Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.

Authors:  Kami J Maddocks; Amy S Ruppert; Gerard Lozanski; Nyla A Heerema; Weiqiang Zhao; Lynne Abruzzo; Arletta Lozanski; Melanie Davis; Amber Gordon; Lisa L Smith; Rose Mantel; Jeffrey A Jones; Joseph M Flynn; Samantha M Jaglowski; Leslie A Andritsos; Farrukh Awan; Kristie A Blum; Michael R Grever; Amy J Johnson; John C Byrd; Jennifer A Woyach
Journal:  JAMA Oncol       Date:  2015-04       Impact factor: 31.777

5.  Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011.

Authors:  Mohammed Al-Hamadani; Thomas M Habermann; James R Cerhan; William R Macon; Matthew J Maurer; Ronald S Go
Journal:  Am J Hematol       Date:  2015-07-27       Impact factor: 10.047

6.  Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.

Authors:  C Y Cheah; D Chihara; J E Romaguera; N H Fowler; J F Seymour; F B Hagemeister; R E Champlin; M L Wang
Journal:  Ann Oncol       Date:  2015-02-23       Impact factor: 32.976

7.  Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.

Authors:  David Chiron; Maurizio Di Liberto; Peter Martin; Xiangao Huang; Jeff Sharman; Pedro Blecua; Susan Mathew; Priyanka Vijay; Ken Eng; Siraj Ali; Amy Johnson; Betty Chang; Scott Ely; Olivier Elemento; Christopher E Mason; John P Leonard; Selina Chen-Kiang
Journal:  Cancer Discov       Date:  2014-07-31       Impact factor: 39.397

8.  The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.

Authors:  Y Cao; Z R Hunter; X Liu; L Xu; G Yang; J Chen; C J Patterson; N Tsakmaklis; S Kanan; S Rodig; J J Castillo; S P Treon
Journal:  Leukemia       Date:  2014-06-10       Impact factor: 11.528

9.  Postibrutinib outcomes in patients with mantle cell lymphoma.

Authors:  Peter Martin; Kami Maddocks; John P Leonard; Jia Ruan; Andre Goy; Nina Wagner-Johnston; Simon Rule; Ranjana Advani; David Iberri; Tycel Phillips; Stephen Spurgeon; Eliana Kozin; Katherine Noto; Zhengming Chen; Wojciech Jurczak; Rebecca Auer; Ewa Chmielowska; Stephan Stilgenbauer; Johannes Bloehdorn; Craig Portell; Michael E Williams; Martin Dreyling; Paul M Barr; Selina Chen-Kiang; Maurizio DiLiberto; Richard R Furman; Kristie A Blum
Journal:  Blood       Date:  2016-01-13       Impact factor: 22.113

10.  Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.

Authors:  Florian Scherer; David M Kurtz; Aaron M Newman; Henning Stehr; Alexander F M Craig; Mohammad Shahrokh Esfahani; Alexander F Lovejoy; Jacob J Chabon; Daniel M Klass; Chih Long Liu; Li Zhou; Cynthia Glover; Brendan C Visser; George A Poultsides; Ranjana H Advani; Lauren S Maeda; Neel K Gupta; Ronald Levy; Robert S Ohgami; Christian A Kunder; Maximilian Diehn; Ash A Alizadeh
Journal:  Sci Transl Med       Date:  2016-11-09       Impact factor: 17.956
View more
  9 in total

1.  Ibrutinib resistance in a patient with transformed diffuse large B-cell lymphoma from primary pulmonary mucosa-associated lymphoid tissue lymphoma.

Authors:  Hong Zhou; Li Yang; Qingxiu Dang; Jianfei Huang; Yuehua Cheng; Yaping Zhang; Wenyu Shi
Journal:  Cancer Biol Ther       Date:  2020-01-13       Impact factor: 4.742

Review 2.  Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies.

Authors:  Danling Gu; Hanning Tang; Jiazhu Wu; Jianyong Li; Yi Miao
Journal:  J Hematol Oncol       Date:  2021-03-06       Impact factor: 17.388

Review 3.  Barriers to achieving a cure in lymphoma.

Authors:  Swetha Kambhampati; Joo Y Song; Alex F Herrera; Wing C Chan
Journal:  Cancer Drug Resist       Date:  2021-11-05

Review 4.  Targeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies.

Authors:  Anagha Deshpande; Javier Munoz
Journal:  Front Oncol       Date:  2022-09-12       Impact factor: 5.738

5.  The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.

Authors:  Guang Yang; Jinhua Wang; Li Tan; Manit Munshi; Xia Liu; Amanda Kofides; Jiaji G Chen; Nicholas Tsakmaklis; Maria G Demos; Maria Luisa Guerrera; Lian Xu; Zachary R Hunter; Jinwei Che; Christopher J Patterson; Kirsten Meid; Jorge J Castillo; Nikhil C Munshi; Kenneth C Anderson; Michael Cameron; Sara J Buhrlage; Nathanael S Gray; Steven P Treon
Journal:  Blood       Date:  2021-11-18       Impact factor: 22.113

Review 6.  Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.

Authors:  C I Edvard Smith; Jan A Burger
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

Review 7.  Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.

Authors:  Deborah M Stephens; John C Byrd
Journal:  Blood       Date:  2021-09-30       Impact factor: 25.476

8.  Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.

Authors:  Laura Ondrisova; Marek Mraz
Journal:  Front Oncol       Date:  2020-10-26       Impact factor: 6.244

9.  Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab.

Authors:  Alessio Bruscaggin; Lodovico Terzi di Bergamo; Valeria Spina; Brendan Hodkinson; Gabriela Forestieri; Ferdinando Bonfiglio; Adalgisa Condoluci; Wei Wu; Maria C Pirosa; Martin R Faderl; Ricardo Koch; Michael Schaffer; John D Alvarez; Nele Fourneau; Bernhard Gerber; Georg Stussi; Emanuele Zucca; Sriram Balasubramanian; Davide Rossi
Journal:  Blood Adv       Date:  2021-11-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.